PNN
New Delhi [India], May 9:
Remlife Global
PTE LTD., a Singapore subsidiary of India’s BSE-listed Remedium Lifecare Ltd., is excited to announce a progressive partnership with JiyaYu Lifesciences PTE Ltd., a company specializing in green chemistry technologies. The joint effort aims at substituting animal-derived raw materials in the production of active pharmaceutical ingredients.
APIs
and sophisticated intermediates using proprietary fermentation and catalyst-driven alternatives.
As part of this collaboration, JiyaYu will provide fully developed and scalable technologies through licensing agreements.
Remlife Global
These technologies are exclusively aimed at replacing conventional animal-based processes with sustainable, economical, and regulation-compliant biotechnological methods.
Remlife Global
Will expand and market these technologies at one or more GMP-compliant contract manufacturing facilities located in India, Singapore, Malta, Ireland, Belgium, and Italy.
JiyaYu Lifesciences has joined forces with a UK-based R&D technology platform specializing in fermentation and biocatalyst-driven substitutes for animal-derived pharmaceutical components. This partnership enables JiyaYu to tap into advanced technologies which they plan to incorporate.
Remlife Global
as fully scalable technologies.
Every technology will come with comprehensive process dossiers along with complete technology transfer documentation, facilitating
Remlife Global
To put into practice, verify, and expand the procedures at the GMP-approved production facilities.
These solutions will support
Remlife Global
His plan aims at reducing reliance on fragile and morally intricate supply chains, all while capitalizing on new business prospects in internationally governed marketplaces.
“Partnering with JiyaYu Lifesciences marks a significant step towards establishing a more ethical, resilient, and sustainable pharmaceutical supply chain,” stated Adarsh Munjal.
Financial Outlook
Every tech platform holds a lowest possible commercial value of Rs50 crore for each offering, with expected EBITDA margins ranging from 20% to 25%. If they manage to launch two products annually, this could lead to significant increases in both total income and profit before interest, taxes, depreciation, and amortization.
-FY26: 2 items | ₹100 Crore turnover | ₹20-25 Crore EBITDA
-FY27: 4 items | ₹200 Crore revenue | ₹40-50 Crore EBITDA
Moving Beyond Animal-Based Inputs
Remlife Global
‘s strategic direction is anchored in the belief that the future of pharmaceuticals lies in sustainable, animal-free production. Key reasons for this shift include:
-Ethical and ESG Alignment: Modern pharmaceutical companies are under growing pressure to remove animal-based components from their supply chains.
– Safety & Quality Assurance: Systems utilizing fermentation and biocatalysts provide enhanced uniformity and remove the possibility of infection from animal-derived contaminants.
-Resilience of Supply Chains: Illnesses, changes in regulations, and unpredictable geopolitical events pose risks to the accessibility of animal-based components.
-Environmental Advantages: Conventional animal-based resources are associated with substantial greenhouse gas emissions, extensive land usage, and significant water consumption.
-Market Drive: Top international pharmaceutical companies are swiftly integrating eco-friendly and animal-testing-free methodologies into their research processes.
About
Remlife Global
PTE LTD.
Remlife Global
PTE LTD serves as the global innovation hub for Remedium Lifecare Ltd. (India), which is a publicly-traded pharmaceutical firm listed on the Bombay Stock Exchange. The organization prioritizes the commercialization of research and development along with forming strategic partnerships.
Remlife Global
Is facilitating the shift towards eco-friendly API contract manufacturing across various international regions.
Media Contact
Adarsh Munjal
Remlife Global
PTE LTD.
Email:
[email protected]
(ADVERTORIAL DISCLOSURE: The aforementioned press release has been supplied by
PNN
ANI shall not bear any responsibility for the content thereof).
Provided by SyndiGate Media Inc.
Syndigate.info
).
Leave a Reply